Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

NCT00787969 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00787969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00787969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
June 15, 2017
Enrollment
74 (estimated)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma